Amgen, AstraZeneca, TEZSPIRE, Tezepelumab-ekko, Eosinophilic Esophagitis, EoE, Phase 3 Clinical Trial, CROSSING Trial, Histologic Remission, Dysphagia, TSLP Inhibition, Gastroenterology

Thousand Oaks, California, United States, October 20, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3...